6/28/23, 11:16 PM MDPIT Pathway Feedback Search Clinical Topics Home Studies MDPIT MDPIT Disease Disease Non-ST-elevation myocardial inf ST-elevation myocardial infarction Trial question What is the effect of diltiazem in patients with previous myocardial infarction? Study design Multi-center Double blinded RCT Population Characteristics of study participants 20.0% female N = 2466 80.0% male 2466 patients (493 female, 1973 male) Inclusion criteria: patients aged 25-75 years with previous myocardial infarction Key exclusion criteria: ongoing cardiogenic shock or symptomatic hypotension; pulmonary hypertension with RV failure; hypersensitivity to diltiazem Interventions N=1232 diltiazem (at a dose of 240 mg/day for 12-52 months) N=1234 placebo (matching placebo for 12-52 months) Primary outcome Death from all causes 13.5 % 13.53 13.47 https://web.pathway.md/studies/recHwWwOymt13Iqe8 1/2 6/28/23, 11:16 PM 3 5 % MDPIT Pathway 3 53 13.47 10.1 % 6.8 % 3.4 % No significant difference 0.0 % Diltiazem Placebo No significant difference in death from all causes (13.47% vs. 13.53%; HR 0.98, 95% CI 0.78 to 1.22) Secondary outcomes No significant difference in first recurrent cardiac event (16.4% vs. 18.31%; HR 0.9, 95% CI 0.74 to 1.08) No significant difference in death from cardiac causes (8.4% vs. 8.9%; ARD 0.5, 95% CI 0 to 1) No significant difference in nonfatal reinfarction (8% vs. 9.4%; ARD -1.4, 95% CI -5.38 to 2.58) Safety outcomes No significant difference in adverse events. Conclusion In patients aged 25-75 years with previous myocardial infarction, diltiazem was not superior to placebo with respect to death from all causes. Reference Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988 Aug 18;319(7):385-92. Open reference URL https://web.pathway.md/studies/recHwWwOymt13Iqe8 2/2